Literature DB >> 16102028

Medical management of peripheral arterial disease.

B L W Bendermacher1, E M Willigendael, J A W Teijink, M H Prins.   

Abstract

Whether symptomatic or not, peripheral arterial disease (PAD), atherosclerosis in the arteries of the lower extremities, is a common disorder in the general population. The prevalence increases with age and under the influence of vascular risk factors. The most classic symptomatic expression of PAD is intermittent claudication. However, the majority of patients with PAD is asymptomatic or has leg symptoms other than classic intermittent claudication. Both symptomatic and asymptomatic subjects with PAD have increased mortality rates, mainly due to cardiovascular and cerebrovascular expressions of atherosclerotic disease. This review focuses on the current available medical therapies for PAD, including risk-factor modification and antiplatelet therapies, as well as strategies for symptomatic relief in both patients with intermittent claudication and patients with critical limb ischemia. In general, risk factor modification and antiplatelet therapy is essential in all patients with PAD to prevent systemic atherosclerotic complications. Furthermore, for symptomatic relief exercise therapy is the main intervention while pharmacological treatment should be only complementary. In patients with critical limb ischemia, when revascularization therapy is not possible, an attempt should be made to avoid amputation with conservative treatment using analgesics, vasodilators and/or anticoagulants. In case of an acute onset of critical limb ischemia, thrombolysis is indicated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102028     DOI: 10.1111/j.1538-7836.2005.01368.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

Review 1.  Ginkgo biloba for intermittent claudication.

Authors:  Saskia P A Nicolaï; Lotte M Kruidenier; Bianca L W Bendermacher; Martin H Prins; Rutger A Stokmans; Pieter P H L Broos; Joep A W Teijink
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

2.  Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice.

Authors:  C Emanueli; A Monopoli; N Kraenkel; M Meloni; S Gadau; I Campesi; E Ongini; P Madeddu
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

3.  Differences in presentation of symptoms between women and men with intermittent claudication.

Authors:  Birgitta Sigvant; Fredrik Lundin; Bo Nilsson; David Bergqvist; Eric Wahlberg
Journal:  BMC Cardiovasc Disord       Date:  2011-06-30       Impact factor: 2.298

4.  The effect of lifestyle and risk factor modification on occlusive peripheral arterial disease outcomes: standard healthcare vs structured programme-for a randomised controlled trial protocol.

Authors:  M Elfghi; F Jordan; D Dunne; I Gibson; J Jones; G Flaherty; S Sultan; W Tawfick
Journal:  Trials       Date:  2021-02-13       Impact factor: 2.279

5.  Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease.

Authors:  Robert G Crowther; Anthony S Leicht; Warwick L Spinks; Kunwarjit Sangla; Frank Quigley; Jonathan Golledge
Journal:  Vasc Health Risk Manag       Date:  2012-04-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.